Method for the treatment of lung tumors

• US 8,623,329 B1
• Filed: 10/07/2010
• Issued: 01/07/2014
• Est. Priority Date: 10/13/2009
• Status: Active Grant

• Current Assignee: Aerophase Inc.
• Original Assignee: Aerophase Inc.
• Inventors: Hansen, Brian Nils, Hybertson, Brooks Michael
• Primary Examiner(s): Alstrum-Acevedo, James H.
• Application Number:
  US12/899,736
• Time in Patent Office: 1,188 Days
• Field of Search: 424/43, 514/449
• US Class Current: 424/43
• CPC Class Codes: A61K 31/337 having four-membered rings, e.g. taxol
• CPC Class Codes: A61K 9/0078 for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions

Abstract

The present invention provides a method of inhibiting cancer growth in the lungs of a mammal through the inhalation administration of aerosol particles of an anti-cancer drug formulation. Further, the present invention provides a formulation for aerosol delivery that comprises a combination of paclitaxel, α-tocopheryl succinate; sorbitan trioleate, ethanol, and carbon dioxide. Prior studies have indicated that aerosol administration of cancer drugs holds great potential as a treatment modality, both for lung cancer and for lung metastases of other cancers. Practice of the invention has been demonstrated using a mouse model of lung cancer, in which intrapulmonary deposition of paclitaxel by aerosol inhalation reduced lung tumor size and increased body weight in tumor-bearing mice.

Claims

1. A method of inhibiting cancer growth in the lungs of a mammal comprising inhalation administration of aerosol particles of a pharmaceutical formulation of an anti-cancer drug comprising paclitaxel, α

-tocopheryl succinate, sorbitan trioleate, ethanol, and carbon dioxide, wherein the pressure of the formulation is maintained between 900 and 5000 psi prior to spraying the formulation through a valve into a region of ambient atmospheric pressure for inhalation administration.

2. The method according to claim 1 wherein the formulation comprises, per one part by weight of paclitaxel, up to 100 parts by weight α

-tocopheryl succinate, up to 200 parts by weight sorbitan trioleate, up to 2000 parts by weight ethanol, and from 100 to 10,000 parts by weight carbon dioxide.

3. The method according to claim 1 wherein the formulation relative mass amounts of paclitaxel, α

-tocopheryl succinate, sorbitan trioleate, ethanol, and carbon dioxide are approximately 1;

5;

11;

97;

3833, respectively.

4. The method according to claim 1 wherein the aerosol of the formulation is diluted with air prior to inhalation to decrease the carbon dioxide level to 0.1 to 10% of the mixture to be inhaled.

5. The method according to claim 1 in which said mammal is given one or more inhalation exposures to said aerosol.

6. The method according to claim 1 in which said cancer is nonsmall cell lung cancer, bronchioloalveolar carcinoma, or metastatic tumors in the lung.

7. The method of claim 1, wherein said cancer is nonsmall cell lung cancer.

8. The method of claim 1, wherein said cancer is bronchioloalveolar carcinoma.

9. The method of claim 1, wherein the pharmaceutical formulation consists of paclitaxel, α

-tocopheryl succinate, sorbitan trioleate, ethanol, and carbon dioxide.

10. A method of treating primary or metastatic lung tumors in a mammal, comprising spraying a pressurized formulation comprising a combination of paclitaxel, α

-tocopheryl succinate, sorbitan trioleate, ethanol, and supercritical carbon dioxide from a high pressure vessel in which the formulation pressure is maintained between 900 and 5000 psi into an atmospheric pressure region to form an airborne aerosol mixture that is subsequently inhaled by said mammal.

11. The method according to claim 10 wherein the formulation comprises, per one part by weight of paclitaxel, up to 100 parts by weight α

-tocopheryl succinate, up to 200 parts by weight sorbitan trioleate, up to 2000 parts by weight ethanol, and from 100 to 10,000 parts by weight carbon dioxide.

12. The method according to claim 10 wherein the airborne aerosol is diluted with air prior to inhalation to decrease the carbon dioxide level to 0.1 to 10% of the mixture to be inhaled.

13. The method according to claim 10 further comprising repetition of said treatment to result in a total of 3 aerosol inhalation exposures per week.

14. The method of claim 10, wherein the pharmaceutical formulation consists of paclitaxel, α

-tocopheryl succinate, sorbitan trioleate, ethanol, and carbon dioxide.